I'm inclined to agree, and I've seen others post the same. However, that's just our opinion. How long this pandemic lasts, how fast we can scale up, whether we dilute the cost and whether this works on other forms of ARDS, are all factors.

Moderate, then mild will be the last groups offered LL. But given enough capacity and research, we may come to a different conclusion ultimately.

Perhaps we discover that one shot of LL in the mild stage prevents progression. It's far too early to tell how it plays out.